Alios BioPharma Presented Positive Results of Its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2 Challenge Study in Adults Infected With Respiratory Syncytial Virus (RSV) at IDWeek - Seite 2
About the RSV Human Challenge Study
The study was conducted at Retroscreen Virology's viral challenge unit in London, UK. The study utilized an adaptive design,
enrolling up to 22 patients per quarantine, with a total of 62 patients enrolled across 3 quarantine periods. The patients were dosed twice daily (BID) for five days approximately 12 hours
after subjects had a documented RSV infection (confirmed by PCR) or from the sixth day after receiving the RSV challenge (whichever came first).
About Respiratory Syncytial Virus (RSV)
RSV is a negative-sense, single-stranded RNA virus from the Paramyxoviridae family and is associated with significant
morbidity in the US and mortality in the developing world. RSV is the most common cause of serious lower respiratory tract infections in infants, and is an important cause of lower respiratory
tract infections in the immunocompromised and in adults with chronic pulmonary diseases such as asthma and COPD. As many as 68% of infants are infected during their first RSV season and nearly
100% of children contract the virus by their second or third year. Currently, there are no effective therapeutics available for treating RSV, limiting treatment to supportive care. RSV
infections have been linked to later development of asthma in children.
About AL-8176
AL-8176 is a nucleoside analog which is being developed by Alios BioPharma as an orally administered antiviral therapy for the treatment of infants infected
with RSV. AL-8176 is designed to inhibit the replication of the RSV by acting on the viral polymerase. In vitro studies of the compound show potent and highly selective inhibition of both RSV
laboratory-adapted A and B strains as well as a range of diverse clinical isolates. Similar to other nucleoside analogs, AL-8176 demonstrates a high barrier to the development of viral resistance.
About Alios BioPharma
Alios BioPharma, Inc. is a clinical stage biopharmaceutical company in South San Francisco, CA that is developing novel therapies for the treatment of viral diseases. The Alios virology
discovery and development platform consists of a proprietary chemical library of nucleoside analogs as well as novel, proprietary virology-based screening systems. Alios is developing a
portfolio of potential therapeutics for viral infections including respiratory syncytial virus (RSV), influenza, rhinovirus, coronavirus and hepatitis C. On September 30, 2014, Johnson &
Johnson (NYSE: JNJ) announced a definitive agreement to acquire Alios for approximately $1.75 billion in cash. The transaction is expected to close in the fourth quarter of 2014. For more
information please visit www.aliosbiopharma.com.
Lesen Sie auch
Alios BioPharma contact:
Bharath Kumandan (Investors & Media)
650-635-5561
Email Contact